Suggestions
Yvonne Lau
Senior Director, Oncology, Quantitative Clinical Pharmacology at Daiichi Sankyo, Inc.
Professional Background
Yvonne Lau is a distinguished leader in the field of biopharmaceutical sciences, with an impressive career that spans over two decades. Currently, she serves as the Senior Director of Oncology at Daiichi Sankyo, Inc., where she plays a pivotal role in advancing quantitative clinical pharmacology initiatives aimed at revolutionizing cancer treatment. Her extensive experience in oncology clinical pharmacology has made her a key figure in the development of groundbreaking therapies designed to improve patient outcomes.
Before her tenure at Daiichi Sankyo, Yvonne held various significant positions at renowned pharmaceutical companies, including The Janssen Pharmaceutical Companies of Johnson & Johnson and Novartis. At Janssen, she served as the Scientific Director of Clinical Pharmacology & Pharmacometrics, where she was instrumental in guiding complex clinical studies that assess the effectiveness and safety of new oncology drugs. Yvonne's leadership capabilities shone through during her time at Novartis, where she ascended through several roles to become the Director and Principal Fellow in Oncology Clinical Pharmacology. Her holistic understanding of the intricacies in drug development and her comprehensive knowledge of pharmacokinetics have greatly contributed to the success of many critical oncology programs.
Yvonne's career began with a strong foundation in science, having worked as a PK Scientist II in Clinical Pharmacology & DMPK at MedImmune and in the Pharmacokinetics & Pharmacometrics Group at Amgen. With her excellent analytical skills and deep understanding of drug behaviors, she was able to influence the direction of pharmacometric methodologies significantly.
Education and Achievements
Yvonne Lau's educational background is equally impressive and serves as the cornerstone of her successful career. She earned a Bachelor of Science in Biomedical Engineering from The Johns Hopkins University, a highly regarded institution known for its strong emphasis on technology and health sciences. This solid educational foundation equipped her with the scientific knowledge and technical skills needed for rigorous research in biopharmaceuticals.
To further her expertise, Yvonne pursued a PhD in Biopharmaceutical Sciences at the University of California, San Francisco. This advanced degree deepened her understanding of drug development processes and equipped her with the tools to navigate complex scientific challenges in pharmacology. Her research during her PhD focused on critical areas of drug metabolism and the pharmacokinetics of therapeutics, preparing her to tackle real-world challenges in the pharmaceutical industry.
Throughout her career, Yvonne has received recognition for her contributions to the field, including presentations at key industry conferences and authorship in peer-reviewed scientific publications. Her commitment to fostering innovation in oncology research underscores her reputation as a thought leader in clinical pharmacology.
Achievements
Yvonne Lau's numerous achievements reflect not only her expertise but also her dedication to advancing the fight against cancer. Some highlights of her career include:
- Leadership in Clinical Trials: Yvonne has led numerous clinical trials that have contributed to the approval of innovative oncology drugs. Her ability to synthesize complex data and drive decision-making processes has been crucial in ensuring that these therapies reach patients in need.
- Development of Pharmacometric Approaches: By pioneering new pharmacometric strategies, Yvonne has significantly improved the accuracy of drug dosing strategies and the prediction of therapeutic outcomes, which is essential for personalized medicine.
- Mentoring Future Scientists: Yvonne is passionate about education and mentorship, frequently providing guidance to young professionals in the biopharmaceutical industry. Her commitment to developing the next generation of scientists is evident in her active involvement in various academic and professional organizations.
- Contributions to Publications: An advocate for sharing knowledge, Yvonne has authored and co-authored numerous publications that have contributed to the advancement of biopharmaceutical sciences, making her a respected voice in her professional community.
Yvonne Lau exemplifies the spirit of innovation and dedication in biopharmaceutical sciences, particularly in oncology. As she continues her journey at Daiichi Sankyo, Yvonne remains committed to pushing the boundaries of science and improving patient care through her expertise in clinical pharmacology and leadership in drug development.